Please use this identifier to cite or link to this item:
|Title:||Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid β load in preclinical Alzheimer's disease.|
|Authors:||Bransby, Lisa;Lim, Yen Ying;Ames, David;Fowler, Christopher;Roberston, Joanne;Harrington, Karra;Snyder, Peter J;Villemagne, Victor L;Salvado, Olivier;Masters, Colin L;Maruff, Paul|
|Affiliation:||CogState Ltd ., Melbourne, VIC, Australia|
Cooperative Research Centre for Mental Health, Parkville, Australia
National Ageing Research Institute, Melbourne, VIC, Australia
Academic Unit for Psychiatry of Old Age, St. Vincent's Health, The University of Melbourne, Melbourne, VIC, Australia
Commonwealth Scientific Industrial Research Organization (CSIRO) Preventative Health National Research Flagship, Australian e-Health Research Centre-BiaMedIA, Brisbane, QLD, Australia
The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Melbourne, VIC, Australia
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia
Ryan Institute for Neuroscience, University of Rhode Island, Kingston, RI, USA..
|Citation:||Journal of clinical and experimental neuropsychology 2019: online first: 29 March|
|Abstract:||Preclinical Alzheimer's disease (AD) is characterized by amyloid-related cognitive decline. Reduction in this decline is used to determine the efficacy of drug therapies designed to forestall the disease in preclinical AD clinical trials, measured by a Preclinical Alzheimer's Cognitive Composite (PACC). Most studies estimate rates of cognitive change by comparing cognitively normal (CN) older adults with abnormally high beta-amyloid (Aβ+) to those with low levels (Aβ-). However, participants of preclinical AD clinical trials must be Aβ+ for entry. Therefore, we estimated the effect of very high amyloid (Aβ++) and Aβ+ on cognitive change over three years measured by different versions of the PACC in individuals with preclinical AD. CN older adults underwent Aβ neuroimaging and neuropsychological assessments over three years as part of the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. Three cognitive composite scores were computed: the Alzheimer's Disease Cooperative Study (ADCS)-PACC, the ADCS-PACC with no Mini-Mental State Examination (MMSE), and the z-scores of Attention, Verbal Fluency and Episodic Memory for Nondemented Older Adults (ZAVEN) composite. Compared to the Aβ++ group, the Aβ+ group showed a slower rate of cognitive decline with the largest magnitude of difference reflected by the ADCS-PACC (d = 0.85). The ADCS-PACC excluding the MMSE and the ZAVEN also reflected a moderate to large magnitude of difference between groups (d = 0.62, d = 0.72, respectively). When all individuals have abnormal Aβ, the level of Aβ at baseline is associated with the rate of subsequent decline. The ADCS-PACC was the most sensitive composite score in showing that lower Aβ is associated with a slower rate of cognitive decline; however, there are limitations to the use of the MMSE. These results provide a benchmark of comparison for preclinical AD clinical trials aiming to slow cognitive deterioration.|
Mini-Mental State Examination
Preclinical Alzheimer’s Cognitive Composite
preclinical Alzheimer’s disease
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.